

FOR THE FINANCIAL PERIOD ENDED 31 December 2022

# under the properties of the control of the desired announcement of the control of the desired the control of th

The Board of Directors of Malaysian Genomics Resource Centre Berhad (hereinafter referred to as "MGRC" or "the Company") and its subsidiaries ("the Group") hereby announce the following unaudited results for the second quarter ended 31 December 2022.

#### A PRESENTATION OF RESULTS

### 1 CONDENSED STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME

	2nd Qua	rter	Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
for the financial period ended	31.12.2022	31.12.2021	31.12.2022	31.12.2021
	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Continuing operations				
Revenue	1,643	7,628	5,455	16,944
Cost of sales	(656)	(5,012)	(1,363)	(12,390)
Gross profit	987	2,616	4,092	4,554
Other income	17	71	60	105
Marketing and distribution	(82)	(51)	(134)	(173)
Finance cost	(25)	(26)	(51)	(54)
Administrative expenses	(2,170)	(1,599)	(4,393)	(3,182)
(Loss)/Profit before taxation	(1,273)	1,011	(426)	1,250
Taxation	-		-	~
(Loss)/Profit for the period	(1,273)	1,011	(426)	1,250
Other comprehensive (loss)/income, net of tax				
Items that will not be reclassified subsequently to profit or loss				
Equity investments measured at fair value through other comprehensive				
loss	(15)	<u> </u>	(15)	
Other comprehensive loss for the period	(15)	-	(15)	
,				
Total comprehensive (loss)/income for the period	{1,288}	1,011	(441)	1,250
(Loss)/Profit attributable to:				
Owners of the parent	(1,233)	1,011	(353)	1,250
Non-controlling interests	(40)	-	(73)	-
(Loss)/Profit for the period	(1,273)	1,011	(426)	1,250
Total comprehensive (loss)/income attributable to:				
Owners of the parent	(1,248)	1,011	(368)	1,250
Non-controlling interests	(40)	-	(73)	-
Total comprehensive (loss)/income for the period	(1,288)	1,011	(441)	1,250
Total completions to the period				
(Loss)/Earnings per share {"{LPS}/EPS"} attributable		•		
to the equity holders of the Company (sen)				
Basic (LPS)/EPS	(0.98)	0.83	(0.28)	1.03
Diluted (LPS)/EPS	N/A	N/A	N/A	N/a

The unaudited condensed statement of profit and loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 30 June 2022 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

There is no income/expense in relation to other income including investment income, gain/loss on disposal of quoted or unquoted investments or properties, gain/loss on derivatives, or exceptional items, except for as disclosed on the cashflow statement.

N/A - Not Applicable



FOR THE FINANCIAL PERIOD ENDED 31 December 2022

#### A PRESENTATION OF RESULTS (cont.)

#### II CONDENSED STATEMENT OF FINANCIAL POSITION

as at	31.12.2022 (RM'000)	30.6.2022 (RM'000)	
	[141 000]	(KINI DOD)	
ASSETS			
NON-CURRENT ASSETS			
Plant and equipment	3,995	4,305	
ntangible assets	4,908	4,950	
light-of-use assets	1,305	1,493	
nvestment in quoted shares	1,032	-	
Deferred tax assets	1,080	1,080	
	12,321	11,828	
CURRENT ASSETS			
rade and other receivables	28,669	8,841	
nventories	449	384	
Other current assets	164	269	
ax recoverable	61	50	
ash and bank balances	3,467	20,518	
	32,810	30,062	
	32,810	30,062	
OTAL ASSETS	45,131	41,890	
QUITY AND EIABILITIES			
QUITY			
hare capital	56,608	52,620	
air value reserve	(15)	,	
ccumulated losses	(15,926)	(15,573)	
quity attributable to the owners of the company	40,667	37,047	
on-controlling interest	1,848	1,921	
OTAL EQUITY	42,515	38,968	
IABILITIES			
ION-CURRENT LIABILITIES			
ease liabilities	1,067	1,259	
	1,067	1,259	
URRENT LIABILITIES			
rade and other payables	1,128	1,235	
ontract liabilities	16	1,233	
ease liabilities	378	366	
rovision for taxation	27	52	
	1,549		
	1,343	1,663	
DTAL LEABILITIES	2,616	2,922	
OTAL EQUITY AND LIABILITIES	45,131	41,890	
let assets (RM'000)	40,667	37,047	
let assets per share attributable to equity holders of the Company (sen)	31.23	29.83	

The unaudited condensed statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 30 June 2022 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

malaysian genomics resource centre


FOR THE FINANCIAL PERIOD ENDED 31 December 2022

# A PRESENTATION OF RESULTS (cont.)

### III CONDENSED STATEMENT OF CHANGES IN EQUITY

for the financial year ended 30 June 2022         (RM'000)		Equity, Total	Non Distributable Share Capital	Fair Value Reserve	Accumulated Losses	Non- Controlling Interest
Total comprehensive income   7,211   1	for the financial year ended 30 June 2022	(RM'000)	(RM'000)	(RM1000)	(RM'000)	(RM'000)
Total comprehensive income   7,211   1		17.020	40.714	-	(22.784)	
Statance of new shares, net of share issuance expenses   11,906   11,906   11,906   -     1,921     -     1,921       1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921   1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921     1,921   1,921     1,921     1,921   1,921     1,921   1,921     1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921	• =		40,714			_
1,921   -   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921	·		11.000		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	_
Acquisition of a Subsidiary   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921   1,921	Issuance of new shares, net of share Issuance expenses		11,906	-		1 021
for the financial period ended 31 December 2022 (RM'000) (RM'000) (RM'000) (RM'000) (RM'000)  Opening balance at 1 July 2022 38,968 52,620 - (15,573) 1,921  Changes in fair value of equity investments measured at fair value through other comprehensive loss (15) - (15) - (353) (73)  Total comprehensive loss (426) (353) (73)  Issuance of new shares, net of share Issuance expenses 3,988 3,988	Acquisition of a subsidiary		-			
Opening balance at 1 July 2022         38,968         \$2,620         -         \$15,573         1,921           Changes in fair value of equity investments measured at fair value through other comprehensive loss         \$(15)         -         \$(15)         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -	Closing balance at 30 June 2022	38,968	52,620	-	(15,573)	1,921
Changes in fair value of equity investments measured at fair value of equity investments measured at fair value through other comprehensive loss  Total comprehensive loss  (15) - (15) - (353) (73) (426) - (353) (73) (426) (426) - (353) (73) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426) (426)	for the financial period ended 31 December 2022	(RM'000)	(RM'000)	(RM'000)	(RM'000)	(RM*000)
Changes in fair value of equity investments measured at fair value through other comprehensive loss  Total comprehensive loss  Issuance of new shares, net of share Issuance expenses  3,988  3,988	Opening balance at 1 July 2022	38,968	52,620	-	(15,573)	1,921
fair value through other comprehensive loss (15) - (15) - Total comprehensive loss (426) (353) (73) Issuance of new shares, net of share Issuance expenses 3,988 3,988						
Total comprehensive loss   (426) (353)   (73)		(15)	-	(15)	-	-
Issuance of new shares, net of share Issuance expenses 3,988 3,988 - 1.248	_ ,	(426)	•	-	(353)	(73)
1948 (15) (15 O26) 1 948		3,988	3,988	-	-	-
	Closing balance at 31 December 2022	42,515	56,608	(15)	(15,926)	1,848

The unaudited condensed statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 30 June 2022 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.




FOR THE FINANCIAL PERIOD ENDED 31 December 2022

# A PRESENTATION OF RESULTS (cont.)

#### IV CONDENSED STATEMENT OF CASH FLOWS

	Year-t	o-Date
	Current Year	Previous Year
for the financial period ended	31.12.2022	31.12.2021
	(RM'000)	(RM'000)
Cash flows from operating activities		
(Loss)/Profit before tax	land	
Adjustments for:	(426)	1,250
Amortisation of Intangible assets	45	
Depreciation	42	46
Fair value gain on equity investment measured at fair value through profit or loss	650	499
Interest income	(10)	-
Interest expenses	(60)	(105)
Operating profit before working capital changes	51	54
(Increase)/Decrease in receivables	247	1,744
Increase in inventories	(19,723)	1,127
Decrease in payables	(65)	(632)
Cash used in operations	(101)	(2,702)
Tax paid	(19,642)	(463)
Interest paid	(36)	(11)
Net cash used in operating activities	(51)	(54)
wer cash used in operating activities	(19,729)	(528)
Cash flows from investing activities		
Interest received	60	105
Purchase of plant and equipment	(153)	(438)
Investment in quoted shares	(1,037)	(120)
Net cash used in investing activities	(1,130)	(333)
Cash flows from financing activities		
Proceeds from issuance of shares, net of share issuance expenses	3,988	11,906
Repayment of lease liabilities	(180)	(169)
Net cash generated from financing activities	3,808	11,737
Net (decrease)/increase in cash and cash equivalents	(17,051)	10,876
Cash and cash equivalents at beginning of the period	20,518	11,308
Cash and cash equivalents at end of period	3,467	22,184
•	3,407	44,184

The unaudited condensed statement of cash flows should be read in conjunction with the audited financial statements for the financial year ended 30 June 2022 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.



FOR THE FINANCIAL PERIOD ENDED 31 December 2022

# UNAUDITED NOTES TO THE INTERIM FINANCIAL STATEMENTS

# B Explanatory Notes Pursuant to MFRS 134

# i Basis of Preparation & Changes in Accounting Policies

These condensed consolidated interim financial statements have been prepared in accordance with MGRC 134 Interim Financial Reporting, and Rule 9.22 and Appendix 9B of the ACE Market Listing Requirements ("Listing Requirements") of Bursa Malaysia Securities Berhad ("Bursa Malaysia").

This report should be read in conjunction with the audited financial statements for the financial year ended 30 June 2022 and the accompanying explanatory notes. The significant accounting policies adopted in preparing these condensed consolidated interim financial statements are consistent with those of the audited financial statements for the financial year ended 30 June 2022.

Details of standards, amendments to published standards and interpretations to existing standards that are applicable to the Company with effect form 1 January 2022 or later are provided in the notes to the audited financial statements of the Group for the financial year ended 30 June 2022. The adoption of these MFRSs does not have any material impact on the Group's results and financial position.

# ii Auditors' Report on Preceding Annual Financial Statements

The audited financial statements for the financial year ended 30 June 2022 were not qualified.

#### iii Seasonal and Cyclical Factors

The operations of MGRC were not significantly affected by seasonal and cyclical factors.

# iv Material and Unusual Items Affecting Assets, Liabilities, Equity, Net Income or Cash Flow

There were no material and unusual items affecting assets, liabilities, equity, net income or cash flows during the financial period.

### v Material Changes in Estimates

There were no material changes in the estimates that had effect(s) on the financial period.

#### vi Debt and Equity Securities

There were no issues, repurchases and repayments of debt and equity securities for the financial period to date.

### malaysian genomics resource centre

# **UNAUDITED SECOND QUARTER REPORT**

FOR THE FINANCIAL PERIOD ENDED 31 December 2022

# B Explanatory Notes Pursuant to MFRS 134 (cont.)

#### vii Dividends Paid

There were no dividends paid for the financial period.

#### viii Segmental Information

MFRS 8 requires identification of reporting segment on the basis of internal reports that are regularly reviewed by the entity's Executive Directors in order to allocate resources to the segment and assess its performance. The management monitors the operating results of the Group as a whole for the purpose of making decisions about resource allocation and performance assessment. Accordingly, the Group has only one reportable segment for the period under review as well as the foreseeable future. Please refer to the financial statements presented in Part A of this announcement.

#### ix Valuation of Plant and Equipment

There has been no valuation made on any of the Group's plant and equipment during the current financial period under review.

#### x Subsequent Events

There were no material events subsequent to the end of the current financial period under review that have not been reflected,

### xi Changes in the Composition of the Group


There were no changes to the composition of the Group in the current quarter under review.

# xii Contingent Liabilities or Contingent Assets

There was no contingent liability or contingent asset arising since the last audited statement of financial position as at 30 June 2022.

#### xiii Capital Commitments

There were no material capital commitments for the purchase of property, plant and equipment that were not provided for in the interim financial statements as at the end of the financial period.



FOR THE FINANCIAL PERIOD ENDED 31 December 2022

# B Explanatory Notes Pursuant to MFRS 134 (cont.)


# xiv Related Party Transactions

Save as disclosed below, the related party transactions during the financial period to date:-

				Quarter	Year-t	o-Date
			Current Year	Previous Year	Current Year	Previous Year
	for the financial period ended Related Party	Nature of Transaction	31.12.2022 (RM'000)	31.12.2021 (RM'000)	31.12.2022 (RM'000)	31.12.2021 (RM'000)
	Aquahealth Sdn Bhd	Interest	44	-	73	-
			44	-	73	_
kv Ca	sh and Cash Equivalents				Current Year	Previous Year
as	at				31.12.2022 (RM'000)	30.6.2022 (RM'000)
Ca	sh on hand and at banks				3,467	1,518
	posits with licensed banks				-	19,000
	ss: Bank overdraft				-	-
	ss: Deposit pledged and with origin	nal maturity period of more the	an 3 months		-	-
LC	11. Deposit piedged dila mili origi.	11			3,467	20,518

#### xvi Inventories

There was no write-down of inventories during the financial period to date.



FOR THE FINANCIAL PERIOD ENDED
31 December 2022

# C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements

These condensed consolidated interim financial statements, for the financial period ended 31 December 2022, have been prepared in accordance with Rule 9.22 and Appendix 9B of the Listing Requirements.

#### i Performance of the Group

#### Current Year 2nd Quarter versus Previous Year 2nd Quarter

For the 2nd quarter ended 31 December 2022, the Group recorded a revenue of RM1.64 million, which represents a reduction of RM5.99 million as compared to a revenue of RM7.63 million for the 2nd quarter in the preceding year. The decrease in revenue was due to the Group's switch from vaccines to immunotherapy and cell therapies under its biopharmaceutical business; organic growth of its genetic screening business; and business development activities including opening new territories and developing new products suitable for the fast-moving consumer good (FMCG) market. This refocusing of the Group's effort towards building its biopharmaceutical business is in support of future growth and sustainability.

For the current quarter, the Group recorded a loss before tax of RM1.27 million compared to a profit before tax of RM1.01 million in the same quarter of the preceding year. The decrease is mainly due to the Group's business expansion and FMCG product development, which require additional human resource capital, research and development expenditure, and marketing.

# Current Year-to-Date versus Previous Year-to-Date

The Group recorded a revenue of RM5.46 million, which represents an decrease of RM11.48 million as compared to a revenue of RM16.94 million in the previous year-to-date. The decrease is mainly due to business switch as mentioned above.


The Group registered a loss before tax of RM0.43 million compared to a profit before tax of RM1.25 million in the corresponding period of the preceding year, mainly due to additional business activities mentioned above.

#### ii Comparison with Preceding Quarter's Results

The comparison of this quarter's results with the preceding quarter is set out below.

for the financial period ended	Current	Preceding Quarter 30.9.2022	Variance	
	(RM'000)	(RM'000)	(RM'000)	
Revenue (Loss)/Profit before tax	1,643 (1,273)	3,812 847	(2,169) (2,120)	

A lower revenue of RM1.64 million was recorded in the current period as compared to the preceding quarter's revenue of RM3.81 million, as the Group laid the groundwork to expand its product and service distribution networks and footprint overseas.



FOR THE FINANCIAL PERIOD ENDED 31 December 2022

### C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

#### iii Prospects of the Group

Malaysian Genomics Resource Centre Berhad ("MGRC" or "The Group") is well-positioned to be a leading provider of genetic screening, genome analysis, and biopharmaceutical products and services in Southeast Asia. Utilising its high-throughput sequencing lab, advanced microarray facility, and state-of-the-art BSL-2 cell processing lab that is cGMP approved by MOH for production of cell and gene therapies, including immunotherapy for various types of cancer, the Group is committed to improving access to the latest in precision and personalised healthcare solutions for patients.

The Group's broad market access and diverse product portfolio have never been greater than they are today. An integral part of this requires increasing the breadth and depth of distribution networks for the Group's products and services. To this end, MGRC seeks and engages with strategic partners across Southeast Asia, the Middle-East North Africa region and, most recently, the United States. To capitalise on its growing distribution network, the Group is applying its genomics and pharmaceutical expertise to develop a portfolio of products for the fast-moving consumer goods market. This includes novel ingredients and finished products for cosmeceuticals, wound healing, and genetic-based fitness improvement programs. Malaysia's National Pharmaceutical Regulatory Agency has approved the first four products and the Group is preparing to distribute them through its network in Southeast Asia.

In Malaysia, the Group works closely with private hospitals and the Ministry of Health to improve access to its immunotherapies.

#### iv Variance from Profit Forecast


The Group did not publish any profit forecast.

#### v Taxation

No taxation was provided for the period as the Group has sufficient unutilised tax losses and unabsorbed capital allowances to set off against taxable profit.

#### vi Status of Corporate Proposal

There is no corporate proposal annonced but not completed as at the date of this announcement, other than the proposed private placement of new ordinary shares in MGRC ("Placement Shares") representing not more than 10% of the issued ordinary shares in MGRC (excluding treasury shares, if any) which was approved on 22 August 2022 ("Private Placement"). MGRC has on 9 December 2022 issued the 1st tranche of 6,000,000 of Placement Shares at RM0.6721 each and the said shares were listed on the same date.



FOR THE FINANCIAL PERIOD ENDED 31 December 2022

#### C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

#### vii Material Litigations

As at the date of this announcement, there is no material litigation against the Group or taken by the Group.

#### viii Dividends

There were no dividends paid for the financial period.

#### ix Trade receivables

The ageing analysis of the Group's trade receivables is as follows:-

	31.12.2022 (RM'000)
Not past due	2,975
Past due - 1 to 30 days	32
- 31 to 60 days	43
- 61 to 90 days	4,142
- more than 90 days	4,170
	8,387
Gross	11,362
Impaired	(470)
Net	10,892

# Receivables that are past due but not impaired


The Group believes that no further impairment allowance is necessary in respect of these trade receivables. They are substantially companies with good collection track record and no recent history of default.

#### x (LPS)/EPS

a) **Basic (LPS)/EPS** Computed by dividing the profit after tax, attributable to owners of the parent for the financial period by the weighted average of the number of ordinary shares in issue during the period.

Basic (LPS)/EPS	2nd Quarter		2nd Quarter Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
for the financial period ended	31.12.2022	31.12.2021	31.12.2022	31.12.2021
(Loss)/Profit after tax, attributable to owners of the parent (RM'000)	(1,233)	1,011	(353)	1,250
Weighted average number of ordinary shares in issue ('000)	125,710	121,856	124,960	121,856
Basic (LPS)/EPS (sen)	(0.98)	0.83	(0.28)	1.03

b) **Diluted (LPS)/EPS.** The Company does not have any convertible shares or convertible financial instruments for the current financial quarter and financial period to date.



FOR THE FINANCIAL PERIOD ENDED 31 December 2022

# C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

хi	Status of Utilisation of Proceed	s				
a)	Proposed utilisation of proceeds from private placement	Proposed utilisation timeframe	Proposed Utilisation (RM'000)	Variation (#) (RM'000)	Actual Utilisation (RM'000)	Balance of Amount Allocated (RM'000)
	Expenses for the private placement	Immediate	361	-	(361)	-
	Working capital	Within 24 months from receipt of funds	23,834	(5,800)	(13,724)	4,310
	Haemodialysis business	Within 24 months from 28 June 2022	•	5,500	(5,500)	-
	Capital expenditure	Within 24 months from 28 June 2022	-	300	(101)	199
		•	24,195	-	(19,686)	4,509
	Haemodialysis business	receipt of funds  Within 24  months from 28  June 2022  Within 24  months from 28	-	5,500	(5,500)	

# Pursuant to the variation of purpose of utilisation of proceeds as announced by the Company on 28 June 2022.

b)	Proposed utilisation of proceeds from private placement	Proposed utilisation timeframe	Proposed Utilisation (RM'000)	Variation (RM'000)	Actual Utilisation (RM'000)	Balance of Amount Allocated (RM'000)
	Future viable investment	Within 24 months from completion	4,033	-	-	4,033
	Purchase of equipment	Within 24 months from completion	-	-	-	-
	Estimated expenses	Upon completion	-	-	±	
			4,033	-	-	4,033

### xii Authorisation for Issue

The interim financial statements were authorised for issue by the Board of Directors of MGRC in accordance with a Resolution of the Directors dated 24 February 2023.

